1. Home
  2. AII vs GLSI Comparison

AII vs GLSI Comparison

Compare AII & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AII

American Integrity Insurance Group Inc.

HOLD

Current Price

$20.00

Market Cap

394.3M

Sector

Finance

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$24.89

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AII
GLSI
Founded
2006
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.3M
372.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AII
GLSI
Price
$20.00
$24.89
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$26.67
$50.00
AVG Volume (30 Days)
124.5K
149.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.62
N/A
Revenue Next Year
$20.51
N/A
P/E Ratio
$4.12
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.78
$7.78
52 Week High
$26.36
$34.10

Technical Indicators

Market Signals
Indicator
AII
GLSI
Relative Strength Index (RSI) 55.58 46.47
Support Level $19.14 $24.00
Resistance Level $20.32 $32.61
Average True Range (ATR) 0.71 2.29
MACD 0.25 -0.19
Stochastic Oscillator 64.04 42.26

Price Performance

Historical Comparison
AII
GLSI

About AII American Integrity Insurance Group Inc.

American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: